Personalized drug safety and targeted drug therapies for individuals with truncating titin variants
Personalized drug safety and targeted drug therapies for individuals with truncating titin variants
针对肌联蛋白截短变异个体的个性化药物安全性和靶向药物治疗
批准号：
490221
负责人：
Laksman Zachary
金额：
$81.92万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-09-01 至 2028-09-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
As many as 1/100 people have a genetic variant called TTNtv. TTNtv affects a large protein that helps the heart to beat. Some kinds of inherited structural heart disease are commonly found in people with TTNtv, and these affect males and females different
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
